Concomitant lack of MMP9 and uPA disturbs physiological tissue remodeling

Developmental Biology

Volumn 358, Issue 1, 2011, Pages 56-67

  Lund, Ida K ^a   Nielsen, Boye S ^a,b   Almholt, Kasper ^a,c   Rønø, Birgitte ^a,d   Hald, Andreas ^a,d   Illemann, Martin ^a   Green, Kirsty A ^a,e   Christensen, Ib J ^a   Rømer, John ^a,c   Lund, Leif R ^a,d  

^a FINSEN LABORATORY   (Denmark)

^b BIONEER A S   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Epistem Ltd   (United Kingdom)

Author keywords

Functional overlap; Genetically modified mice; Matrix metalloproteinase; Plasminogen activators; Proteases; Tissue remodeling

Indexed keywords

GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE GROWTH; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSIOLOGICAL PROCESS; PREGNANCY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SKIN INJURY; TISSUE REPAIR; UPREGULATION; WOUND HEALING;

MUS;

EID: 80052620505     PISSN: 00121606     EISSN: 1095564X     Source Type: Journal    
DOI: 10.1016/j.ydbio.2011.07.021     Document Type: Article

References (73)

1. Afonso S., Romagnano L., Babiarz B. The expression and function of cystatin C and cathepsin B and cathepsin L during mouse embryo implantation and placentation. Development 1997, 124:3415-3425.
2. Alexander C.M., Hansell E.J., Behrendtsen O., Flannery M.L., Kishnani N.S., Hawkes S.P., Werb Z. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 1996, 122:1723-1736.
3. Almholt K., Green K.A., Juncker-Jensen A., Nielsen B.S., Lund L.R., Rømer J. Extracellular proteolysis in transgenic mouse models of breast cancer. J. Mammary Gland Biol. Neoplasia. 2007, 12:83-97.
4. Almholt K., Juncker-Jensen A., Lærum O.D., Danø K., Johnsen M., Lund L.R., Rømer J. Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol. Cancer Ther. 2008, 7:2758-2767.
5. Almholt K., Junker-Jensen A., Green K.A., Solberg H., Lund L.R., Rømer J. The plasminogen activation system in tissue remodeling and cancer invasion 2008, 203-221. The Cancer Degradome Springer, New York. D. Edwards, G. Høyer-Hansen, F. Blasi, B.F. Sloane (Eds.).
6. Balbin M., Fueyo A., Knauper V., Lopez J.M., Alvarez J., Sanchez L.M., Quesada V., Bordallo J., Murphy G., Lopez-Otin C. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 2001, 276:10253-10262.
7. Beare A.H., O'Kane S., Krane S.M., Ferguson M.W. Severely impaired wound healing in the collagenase-resistant mouse. J. Invest. Dermatol. 2003, 120:153-163.
8. Bolon I., Zhou H.M., Charron Y., Wohlwend A., Vassalli J.D. Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am. J. Pathol. 2004, 164:2299-2304.
9. Bugge T.H., Flick M.J., Daugherty C.C., Degen J.L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995, 9:794-807.
10. Bugge T.H., Suh T.T., Flick M.J., Daugherty C.C., Rømer J., Solberg H., Ellis V., Danø K., Degen J.L. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 1995, 270:16886-16894.
11. Bugge T.H., Flick M.J., Danton M.J., Daugherty C.C., Rømer J., Danø K., Carmeliet P., Collen D., Degen J.L. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5899-5904.
12. Bullard K.M., Lund L., Mudgett J.S., Mellin T.N., Hunt T.K., Murphy B., Ronan J., Werb Z., Banda M.J. Impaired wound contraction in stromelysin-1-deficient mice. Ann. Surg. 1999, 230:260-265.
13. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424.
14. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2007, 42:113-185.
15. Connolly B.M., Choi E.Y., Gårdsvoll H., Bey A.L., Currie B.M., Chavakis T., Liu S., Molinolo A., Ploug M., Leppla S.H., Bugge T.H. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood 2010, 116:1593-1603.
16. Cross J.C., Werb Z., Fisher S.J. Implantation and the placenta: key pieces of the development puzzle. Science 1994, 266:1508-1518.
17. Danø K., Behrendt N., Høyer-Hansen G., Johnsen M., Lund L.R., Ploug M., Rømer J. Plasminogen activation and cancer. Thromb. Haemost. 2005, 93:676-681.
18. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 1991, 266:12752-12758.
19. Felbor U., Kessler B., Mothes W., Goebel H.H., Ploegh H.L., Bronson R.T., Olsen B.R. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7883-7888.
20. Frøssing S., Rønø B., Hald A., Rømer J., Lund L.R. Skin wound healing in MMP2-deficient and MMP2/plasminogen double-deficient mice. Exp. Dermatol. 2010, 19:e234-e240.
21. Grøndahl-Hansen J., Lund L.R., Ralfkiær E., Ottevanger V., Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J. Invest Dermatol. 1988, 90:790-795.
22. Gutierrez-Fernandez A., Inada M., Balbin M., Fueyo A., Pitiot A.S., Astudillo A., Hirose K., Hirata M., Shapiro S.D., Noel A., Werb Z., Krane S.M., Lopez-Otin C., Puente X.S. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J. 2007, 21:2580-2591.
23. Hald A., Rønø B., Melander M.C., Ding M., Holck S., Lund L.R. MMP9 is protective against lethal inflammatory mass lesions in the mouse colon. Dis. Model. Mech. 2011, 4:212-227.
24. Hartenstein B., Dittrich B.T., Stickens D., Heyer B., Vu T.H., Teurich S., Schorpp-Kistner M., Werb Z., Angel P. Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. J. Invest. Dermatol. 2006, 126:486-496.
25. Heissig B., Lund L.R., Akiyama H., Ohki M., Morita Y., Rømer J., Nakauchi H., Okumura K., Ogawa H., Werb Z., Danø K., Hattori K. The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell. 2007, 1:658-670.
26. Holst-Hansen C., Low J.A., Stephens R.W., Johnson M.D., Carmeliet P., Frandsen T.L., Brünner N., Dickson R.B. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. Breast Cancer Res. Treat. 2001, 68:225-237.
27. Hoover-Plow J.L., Gong Y., Shchurin A., Busuttil S.J., Schneeman T.A., Hart E. Strain and model dependent differences in inflammatory cell recruitment in mice. Inflamm. Res. 2008, 57:457-463.
28. Hu D., Cross J.C. Development and function of trophoblast giant cells in the rodent placenta. Int. J. Dev. Biol. 2010, 54:341-354.
29. Illemann M., Bird N., Majeed A., Lærum O.D., Lund L.R., Danø K., Nielsen B.S. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int. J Cancer. 2009, 124:1860-1870.
30. Jögi A., Pass J., Høyer-Hansen G., Lund L.R., Nielsen B.S., Danø K., Rømer J. Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice. J. Thromb. Haemost. 2007, 5:1936-1944.
31. Jögi A., Rønø B., Lund I.K., Nielsen B.S., Ploug M., Høyer-Hansen G., Rømer J., Lund L.R. Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice. PLoS ONE. 2010, 5:e12746.
32. Juncker-Jensen A., Lund L.R. Phenotypic overlap between MMP-13 and the plasminogen activation system during wound healing in mice. PLoS ONE. 2011, 6:e16954.
33. Kristensen P., Eriksen J., Danø K. Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J. Histochem. Cytochem. 1991, 39:341-349.
34. Kyriakides T.R., Wulsin D., Skokos E.A., Fleckman P., Pirrone A., Shipley J.M., Senior R.M., Bornstein P. Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol. 2009, 28:65-73.
35. Laird P.W., Zijderveld A., Linders K., Rudnicki M.A., Jaenisch R., Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991, 19:4293.
36. Lambert V., Wielockx B., Munaut C., Galopin C., Jost M., Itoh T., Werb Z., Baker A., Libert C., Krell H.W., Foidart J.M., Noel A., Rakic J.M. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003, 17:2290-2292.
37. Lelongt B., Bengatta S., Delauche M., Lund L.R., Werb Z., Ronco P.M. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp. Med. 2001, 193:793-802.
38. Leonardsson G., Peng X.R., Liu K., Nordstrom L., Carmeliet P., Mulligan R., Collen D., Ny T. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc. Natl. Acad. Sci U. S. A. 1995, 92:12446-12450.
39. Lin L., Gårdsvoll H., Huai Q., Huang M., Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J. Biol. Chem. 2010, 285:10982-10992.
40. Lund L.R., Rømer J., Thomasset N., Solberg H., Pyke C., Bissell M.J., Danø K., Werb Z. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996, 122:181-193.
41. Lund L.R., Rømer J., Bugge T.H., Nielsen B.S., Frandsen T.L., Degen J.L., Stephens R.W., Danø K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999, 18:4645-4656.
42. Lund L.R., Green K.A., Stoop A.A., Ploug M., Almholt K., Lilla J., Nielsen B.S., Christensen I.J., Craik C.S., Werb Z., Danø K., Rømer J. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J. 2006, 25:2686-2697.
43. Lund I.K., Jögi A., Rønø B., Rasch M.G., Lund L.R., Almholt K., Gårdsvoll H., Behrendt N., Rømer J., Høyer-Hansen G. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J. Biol. Chem. 2008, 283:32506-32515.
44. Madlener M., Parks W.C., Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp. Cell Res. 1998, 242:201-210.
45. Marotti K.R., Belin D., Strickland S. The production of distinct forms of plasminogen activator by mouse embryonic cells. Dev. Biol. 1982, 90:154-159.
46. Martin P. Wound healing -- aiming for perfect skin regeneration. Science 1997, 276:75-81.
47. Martin M.D., Carter K.J., Jean-Philippe S.R., Chang M., Mobashery S., Thiolloy S., Lynch C.C., Matrisian L.M., Fingleton B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 2008, 68:6251-6259.
48. Mirastschijski U., Zhou Z., Rollman O., Tryggvason K., Agren M.S. Wound healing in membrane-type-1 matrix metalloproteinase-deficient mice. J. Invest. Dermatol. 2004, 123:600-602.
49. Mohan R., Chintala S.K., Jung J.C., Villar W.V., McCabe F., Russo L.A., Lee Y., McCarthy B.E., Wollenberg K.R., Jester J.V., Wang M., Welgus H.G., Shipley J.M., Senior R.M., Fini M.E. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J. Biol. Chem. 2002, 277:2065-2072.
50. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
51. Perez S.E., Cano D.A., Dao-Pick T., Rougier J.P., Werb Z., Hebrok M. Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Diabetes 2005, 54:694-701.
52. Ploplis V.A., Carmeliet P., Vazirzadeh S., Van V.I., Moons L., Plow E.F., Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995, 92:2585-2593.
53. Quigley D.A., To M.D., Pérez-Losada J., Pelorosso F.G., Mao J.H., Nagase H., Ginzinger D.G., Balmain A. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 2009, 458:505-508.
54. Rasch M.G., Lund I.K., Illemann M., Høyer-Hansen G., Gårdsvoll H. Purification and characterization of recombinant full-length and protease domain of murine MMP-9 expressed in Drosophila S2 cells. Protein Expr. Purif. 2010, 72:87-94.
55. Rømer J., Lund L.R., Eriksen J., Pyke C., Kristensen P., Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 1994, 102:519-522.
56. Rømer J., Bugge T.H., Pyke C., Lund L.R., Flick M.J., Degen J.L., Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. 1996, 2:287-292.
57. Rømer J., Nielsen B.S., Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr. Pharm. Des. 2004, 10:2359-2376.
58. Rudolph-Owen L.A., Hulboy D.L., Wilson C.L., Mudgett J., Matrisian L.M. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 1997, 138:4902-4911.
59. Saghatelian A., Jessani N., Joseph A., Humphrey M., Cravatt B.F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10000-10005.
60. Sappino A.P., Huarte J., Belin D., Vassalli J.D. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J. Cell Biol. 1989, 109:2471-2479.
61. Schäfer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9:628-638.
62. Screen M., Dean W., Cross J.C., Hemberger M. Cathepsin proteases have distinct roles in trophoblast function and vascular remodelling. Development 2008, 135:3311-3320.
63. Selvarajan S., Lund L.R., Takeuchi T., Craik C.S., Werb Z. A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat. Cell Biol. 2001, 3:267-275.
64. Singer A.J., Clark R.A. Cutaneous wound healing. N. Engl. J Med. 1999, 341:738-746.
65. Solberg H., Rinkenberger J., Danø K., Werb Z., Lund L.R. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 2003, 130:4439-4450.
66. Stephens R.W., Pöllänen J., Tapiovaara H., Leung K.C., Sim P.S., Salonen E.M., Rønne E., Behrendt N., Danø K., Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol. 1989, 108:1987-1995.
67. Teesalu T., Blasi F., Talarico D. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development. Dev. Dyn. 1998, 213:27-38.
68. Teesalu T., Masson R., Basset P., Blasi F., Talarico D. Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation. Dev. Dyn. 1999, 214:248-258.
69. Toriseva M., Kähäri V.M. Proteinases in cutaneous wound healing. Cell Mol. Life Sci. 2009, 66:203-224.
70. Uttamchandani M., Wang J., Li J., Hu M., Sun H., Chen K.Y., Liu K., Yao S.Q. Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library. J. Am. Chem. Soc. 2007, 129:7848-7858.
71. Varanou A., Withington S.L., Lakasing L., Williamson C., Burton G.J., Hemberger M. The importance of cysteine cathepsin proteases for placental development. J Mol. Med. 2006, 84:305-317.
72. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
73. Zhou H.M., Nichols A., Meda P., Vassalli J.D. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 2000, 19:4817-4826.